Biogen

In News

An experimental Alzheimer's drug shows promise targeting a different brain protein, new study shows - AP News

AP News - Jul 14, 2026

Exclusive: Genetic medicine startup launches to speed programs that stalled at Editas, Biogen - Endpoints News

Endpoints News - Jul 14, 2026

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease - Biogen

Biogen - Jul 14, 2026

What a new Alzheimer’s drug could mean for the future of treatment - The Boston Globe

The Boston Globe - Jul 17, 2026

AAIC26: Biogen stock drops after unveiling tau-targeting ASO data - Clinical Trials Arena

Clinical Trials Arena - Jul 15, 2026

Biogen moves forward with Alzheimer's drug candidate following phase 2 study - medwatch.com

medwatch.com - Jul 16, 2026

Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact - Yahoo Finance

Yahoo Finance - Jul 15, 2026

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment - Biogen

Biogen - Jul 14, 2026

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug - Reuters

Reuters - Jul 13, 2026

Pharmalittle: We're reading about a Biogen Alzheimer's drug, skyrocketing 340B drug sales, and more - STAT

STAT - Jul 15, 2026

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease - Biogen

Biogen - Jul 13, 2026

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026 - Biogen

Biogen - Jul 12, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment